We also identified that both DCLK1-L variants exhibit pro-oncogenic roles, promoting cancer stemness and aggressiveness, and that DCLK1-L inhibition can significantly attenuate ccRCC malignancy in vitro and in vivo. Here, DCLK1 is linked to nonpapillary renal cell carcinoma.